预约演示

Inovio hopes Ebola vaccine booster data can provide a shot in the arm

2023-02-02

疫苗临床1期临床结果

Inovio is in need of good news from the clinic after its early efforts to develop a COVID-19 vaccine ran into trouble.

Inovioafter imposing a second round of layoffs, Inovio revealed a small data set forCOVID-19la vaccine booster, which the company hopes could someday also boost its fortunes.

INO-4201 was tested in a phase 1b study in 46 heInoviovolunteers who had previously received Merck & Co.’s Ebola vaccine Ervebo three to seven years prior. The 36 participants who received the shot responded, with boosted neutralizing titers maintained 24 weeks later.

INO-4201 received a 1-mg dose, which was injected intradermally followed by electroportation Merck & Co.o's Cellectra devErveboellectra is a hand-held device that uses a brief electrical pulse to allow plasmids to enter cells through temporary pores.

Inovio is working with Global Urgent and Advanced Research and Development, or GuardRX, through funInoviorom the U.S. Defense Advanced Research Projects Agency, or DARPA, and Geneva University Hospitals. The company expects to reveal more data in a peer-reviewed journal at a later date.

Inovionnsylvania biotech is in need of good news from the clinic, after its early efforts to develop a COVID-19 vaccine ran into trouble in 2021 while other companies got to the finish line faster. With that disappointment, Inovio's tough times continued, culminating in two rounds of layoffs, most recently on Wednesday when 11% of the workforce was let go.

In the strategic reorganization announced this week, Inovio said its lead programs were treatments for COVID-19ciated diseases. This includes recurrent respiratory papillomatosis candidate INO-3107 and VGX-3100 for cervical Inoviorade squamous intraepithelial lesions. The company is expecting data from both programs in the third quarter.